These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25485306)

  • 1. Molecular Targets and Treatment of Meningioma.
    Miller R; DeCandio ML; Dixon-Mah Y; Giglio P; Vandergrift WA; Banik NL; Patel SJ; Varma AK; Das A
    J Neurol Neurosurg; 2014; 1(1):. PubMed ID: 25485306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology of brain meningiomas.
    Byvalsev VA; Stepanov IA; Belykh EG; Yarullina AI
    Patol Fiziol Eksp Ter; 2017; 61(2):82-91. PubMed ID: 29215848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
    Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
    Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics of meningiomas: from basic research to potential clinical applications.
    Simon M; Boström JP; Hartmann C
    Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of meningiomas.
    Ragel BT; Jensen RL
    Neurosurg Focus; 2005 Nov; 19(5):E9. PubMed ID: 16398473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
    Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
    Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.
    Pham MH; Zada G; Mosich GM; Chen TC; Giannotta SL; Wang K; Mack WJ
    Neurosurg Focus; 2011 May; 30(5):E7. PubMed ID: 21529178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
    Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of meningiomas.
    Perry A; Gutmann DH; Reifenberger G
    J Neurooncol; 2004 Nov; 70(2):183-202. PubMed ID: 15674477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current standing and frontiers of gene therapy for meningiomas.
    De La Garza-Ramos R; Flores-Rodríguez JV; Martínez-Gutiérrez JC; Ruiz-Valls A; Caro-Osorio E
    Neurosurg Focus; 2013 Dec; 35(6):E4. PubMed ID: 24289129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.
    Ikeda K; Saeki Y; Gonzalez-Agosti C; Ramesh V; Chiocca EA
    J Neurosurg; 1999 Jul; 91(1):85-92. PubMed ID: 10389885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.
    Buccoliero AM; Gheri CF; Castiglione F; Ammannati F; Gallina P; Taddei A; Garbini F; Rossi Degl'Innocenti D; Arganini L; Di Lorenzo N; Mennonna P; Taddei GL
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):353-7. PubMed ID: 17721284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningioma: an update.
    Lusis E; Gutmann DH
    Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3.
    Di Nunno V; Giannini C; Asioli S; Conti A; Furtner J; Balestrini D; Tosoni A
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230612
    [No Abstract]   [Full Text] [Related]  

  • 18. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
    Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
    Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
    Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
    Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
    Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
    J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.